Latest profit margin for Alterity Therapeutics: -396.9% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Dec 2025
Trailing 12 months ending Dec 2025
Alterity Therapeutics posts a profit margin of -396.9% as of December 2025. That compares with -1440.79% in the prior-year period — up 72.5% year over year. That is below the Healthcare sector average of 13.89%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Alterity Therapeutics's profit margin was -1440.79%. The latest reading is -396.9% — a 72.5% year-over-year increase (period ending December 2025). Use the history and growth charts on this page for a longer lookback.
For Healthcare stocks, a profit margin near 13.89% is typical. Alterity Therapeutics's -396.9% is lower that level. That is roughly 2956.8% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Alterity Therapeutics's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -396.9% as of December 2025; use YoY and peer views to separate noise from signal.
Context for ATHE's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.89%), and (3) consistency with growth and profitability. This page covers the first two; Alterity Therapeutics's other metric pages and overview cover the third.